HRP20040181A2 - Use of atazanavir in hiv therapy - Google Patents

Use of atazanavir in hiv therapy

Info

Publication number
HRP20040181A2
HRP20040181A2 HR20040181A HRP20040181A HRP20040181A2 HR P20040181 A2 HRP20040181 A2 HR P20040181A2 HR 20040181 A HR20040181 A HR 20040181A HR P20040181 A HRP20040181 A HR P20040181A HR P20040181 A2 HRP20040181 A2 HR P20040181A2
Authority
HR
Croatia
Prior art keywords
atazanavir
hiv
protease inhibitor
triglyceride levels
hiv therapy
Prior art date
Application number
HR20040181A
Other languages
English (en)
Inventor
Clifford M Bechtold
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HRP20040181A2 publication Critical patent/HRP20040181A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HR20040181A 2001-08-31 2002-08-21 Use of atazanavir in hiv therapy HRP20040181A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31674501P 2001-08-31 2001-08-31
PCT/US2002/026675 WO2003020206A2 (en) 2001-08-31 2002-08-21 Use of atazanavir in hiv therapy

Publications (1)

Publication Number Publication Date
HRP20040181A2 true HRP20040181A2 (en) 2004-08-31

Family

ID=23230468

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040181A HRP20040181A2 (en) 2001-08-31 2002-08-21 Use of atazanavir in hiv therapy

Country Status (27)

Country Link
US (1) US20030045501A1 (pl)
EP (1) EP1420799B1 (pl)
JP (1) JP2005501880A (pl)
KR (1) KR20040029447A (pl)
CN (1) CN1245988C (pl)
AT (1) ATE341332T1 (pl)
AU (1) AU2002332610B2 (pl)
BG (1) BG108585A (pl)
BR (1) BR0211544A (pl)
CA (1) CA2458807A1 (pl)
CZ (1) CZ2004288A3 (pl)
DE (1) DE60215189T2 (pl)
DK (1) DK1420799T3 (pl)
EE (1) EE200400065A (pl)
ES (1) ES2274119T3 (pl)
HR (1) HRP20040181A2 (pl)
HU (1) HUP0401091A2 (pl)
IL (1) IL159849A0 (pl)
IS (1) IS7158A (pl)
MX (1) MXPA04001721A (pl)
NO (1) NO20040803L (pl)
NZ (1) NZ530722A (pl)
PL (1) PL367873A1 (pl)
RU (1) RU2316341C2 (pl)
WO (1) WO2003020206A2 (pl)
YU (1) YU12204A (pl)
ZA (1) ZA200401412B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680099B1 (en) * 2003-11-07 2009-04-15 JJ Pharma, Inc. Hdl-boosting combination therapy complexes
US20050148523A1 (en) * 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
ATE536343T1 (de) 2007-06-12 2011-12-15 Concert Pharmaceuticals Inc Azapeptid-derivate als hiv-protease-inhibitoren
PL2170292T3 (pl) * 2007-06-22 2014-06-30 Bristol Myers Squibb Holdings Ireland Tabletkowane kompozycje zawierające atazanawir
JP2010530889A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
JP2010530890A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
ATE503467T1 (de) * 2007-06-22 2011-04-15 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
EP2214668A1 (en) * 2007-10-29 2010-08-11 Cipla Limited Novel antiretroviral combination
CN101249138B (zh) * 2008-03-28 2012-03-21 中国人民解放军军事医学科学院野战输血研究所 一种含五味子乙醇提取物的抗艾滋病药物组合物
WO2011121558A1 (en) * 2010-04-02 2011-10-06 Phivco-1 Llc Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2188638C2 (ru) * 1996-04-04 2002-09-10 Шионоги Энд Ко., Лтд. Анти-вич-композиция, содержащая имидазольные производные

Also Published As

Publication number Publication date
KR20040029447A (ko) 2004-04-06
PL367873A1 (pl) 2005-03-07
MXPA04001721A (es) 2004-05-31
YU12204A (sh) 2006-08-17
EP1420799A4 (en) 2004-11-24
DE60215189D1 (de) 2006-11-16
DK1420799T3 (da) 2007-01-15
ZA200401412B (en) 2005-03-18
NZ530722A (en) 2007-11-30
CN1245988C (zh) 2006-03-22
IL159849A0 (en) 2004-06-20
HUP0401091A2 (hu) 2004-08-30
DE60215189T2 (de) 2007-10-25
CZ2004288A3 (cs) 2004-12-15
BG108585A (bg) 2005-04-30
US20030045501A1 (en) 2003-03-06
EP1420799B1 (en) 2006-10-04
IS7158A (is) 2004-02-19
BR0211544A (pt) 2004-07-13
JP2005501880A (ja) 2005-01-20
ES2274119T3 (es) 2007-05-16
HK1061640A1 (en) 2004-09-30
WO2003020206A3 (en) 2003-10-02
NO20040803L (no) 2004-02-24
CA2458807A1 (en) 2003-03-13
EP1420799A2 (en) 2004-05-26
EE200400065A (et) 2004-06-15
RU2316341C2 (ru) 2008-02-10
WO2003020206A2 (en) 2003-03-13
ATE341332T1 (de) 2006-10-15
AU2002332610B2 (en) 2007-11-08
CN1547476A (zh) 2004-11-17

Similar Documents

Publication Publication Date Title
IL159849A0 (en) Use of atazanavir in hiv therapy
EP4445900A3 (en) Therapeutic compounds for hiv virus infection
TW200510397A (en) Conjugated complement cascade inhibitors
SI1677827T1 (sl) Zdravilni sestavek proti virusu hepatitisa c (hcv)
ECSP034922A (es) Pirrolopirimidinas
EP1284140A3 (en) Use of ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating aids
AU2002302587A1 (en) Acne treatment with lipooxigenase inhibitors
ATE534433T1 (de) Kombinierte verwendung von enzyminhibitoren zur therapie und prävention allergischer reaktionen vom typ i nach gell und coombs und zur therapie und prävention dermatologischer erkrankungen mit follikulären und epidermalen hyperkeratosen und einer verstärkten keratinozytenproliferation
AP1727A (en) Methods and compositions for treating flaviviruses and pestiviruses.
WO2003024386A8 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
DE60107065D1 (de) Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut
AU7371600A (en) Use of alpha-linolenic acid metabolites for treatment or prevention of cancer
AU2003219107A1 (en) Tuberculosis treatment using pleuromutilin derivatives
MX2010002909A (es) Metodo de tratamiento de pacientes de hepatitis c.
EA200702242A1 (ru) Использование сульфонамидного соединения для улучшения фармакокинетики лекарственного средства
AU8647101A (en) Compounds having activity as inhibitors of cytochrome p450rai
MX2024015041A (es) Fitusiran para el tratamiento de la hemofilia a y b
NO20053455L (no) Anvendelse av en kombinasjon inneholdende en ikke-nukleosid revers transkriptase inhibitor (NNRTI) med en inhibitor av cytokrom P450 sa som protease inhibitorer
RU2004106787A (ru) Применение атазанавира в терапии вич-инфекции
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
MX2020005029A (es) Metodos y composiciones para el mejoramiento de la funcion lisosomal y tratamiento de enfermedad neurodegenerativa.
MXPA05005911A (es) Utilizacion del acido docosahexaenoico como sustancia activa para el tratamiento de la lipodistrofia.
AU4111600A (en) The use of gssg reductase for the therapy and prophylaxis of hiv infected patients
WO2022092907A3 (ko) 다부위에 적용가능한 플라즈마 치료기
WO2021262437A3 (en) Use of il13 for prevention and treatment of covid-19

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20070801

Year of fee payment: 6

ODBI Application refused